scroll
LEARN MORE
PULSE CHECK WEBINAR: Portfolio positioning towards FY26
Close
Friday 30th May – Dow up +117pts, SPI down -17pts
Close
Gerrish: The correction is done, we’re positioning for what comes next
Close
Active Growth Portfolio – Showing Weighted Beta
Close
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
TLX $26.10
20 MINUTE DELAYED
ANALYSIS
OPINION
ACTION
i
PERFORMANCE
i
| SHARE PRICE ACTIVITY | |
|---|---|
| Last (Price) | 26.10 |
| Change | 0.00 (0.00) |
| Bid / Ask | 0.00 - 0.00 |
| Volume | 0 |
| Turnover | 0 |
| Open | 0.00 |
| Day Range | 25.38 - 26.13 |
| VWAP | 0.00 |
| Prev Close | 26.10 |
| Last Trade | 30/05 4:10pm (AEST) |
i
| KEY INFORMATION | |
|---|---|
| Sector | Healthcare |
| Shares Issued | 196,012,086 |
| NTA/Share | 0.00 |
| Last Dividend | 0.00 |
| Dividend Ex Date | 0 |
| Dividend Pay Date | 0 |
i
| CURRENT () | |
|---|---|
| Revenue | |
| EBITDA | |
| Profit | |
| Earnings Per Share (EPS) | 0 |
| Dividend Per Share (DPS) | 0 |
| Yield % | 0.00 |
| Market Cap | 0 |
| Price to Earnings Ratio (P/E) | 180.5 |
i
TARGET PRICE FORECAST
i
| ESTIMATES () | |
|---|---|
| Revenue | 0.00 |
| EBITDA | 0.00 |
| Profit | 0.00 |
| Earnings Per Share (EPS) | 0.00 |
| Dividend Per Share (DPS) | 0.00 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
0.00
Lt Growth Rate
0.00
Recommendation ()
0.00
Business Summary
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. Its lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.
Relevant suggested news and content from the site
Video
WATCH
PULSE CHECK WEBINAR: Portfolio positioning towards FY26
FY26 is shaping up as a year where strategic portfolio positioning will matter more than ever. Hear from James Gerrish & Shawn Hickman as they detail MM's current views.
Podcast
LISTEN
Friday 30th May – Dow up +117pts, SPI down -17pts
Daily Podcast Direct from the Desk
Video
WATCH
Gerrish: The correction is done, we’re positioning for what comes next
The Market Matters lead portfolio manager talks the recent recovery, Trump, gold, and why he thinks there's plenty of opportunities.
chart
Active Growth Portfolio – Showing Weighted Beta
Only available to Members
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing.
Click here
